Biomarkers of immune dysfunction following combination antiretroviral therapy for HIV infection.
about
Can immunotherapy be useful as a "functional cure" for infection with Human Immunodeficiency Virus-1?Impact of antiretroviral therapy (ART) timing on chronic immune activation/inflammation and end-organ damageMulti-dose Romidepsin Reactivates Replication Competent SIV in Post-antiretroviral Rhesus Macaque ControllersDissecting How CD4 T Cells Are Lost During HIV InfectionA consensus surface activation marker signature is partially dependent on human immunodeficiency virus type 1 Nef expression within productively infected macrophagesThe Effect of a Community-Based Exercise Program on Inflammation, Metabolic Risk, and Fitness Levels Among Persons Living with HIV/AIDS.Tobacco smoking increases immune activation and impairs T-cell function in HIV infected patients on antiretrovirals: a cross-sectional pilot studySignificance and clinical management of persistent low-level viremia and very-low-level viremia in HIV-1-infected patients.Residual immune dysregulation syndrome in treated HIV infection.Limited HIV infection of central memory and stem cell memory CD4+ T cells is associated with lack of progression in viremic individuals.Immune activation and HIV persistence: implications for curative approaches to HIV infection.Circulating heat shock protein 60 levels are elevated in HIV patients and are reduced by anti-retroviral therapyKinetics of microbial translocation markers in patients on efavirenz or lopinavir/r based antiretroviral therapy.Low levels of microbial translocation marker LBP are associated with sustained viral response after anti-HCV treatment in HIV-1/HCV co-infected patients.Understanding the MIND phenotype: macrophage/microglia inflammation in neurocognitive disorders related to human immunodeficiency virus infection.Novel sensitive real-time PCR for quantification of bacterial 16S rRNA genes in plasma of HIV-infected patients as a marker for microbial translocation.Bone health in HIV-infected children, adolescents and young adults: a systematic review.Targeting HIV Reservoir in Infected CD4 T Cells by Dual-Affinity Re-targeting Molecules (DARTs) that Bind HIV Envelope and Recruit Cytotoxic T Cells.Dysregulated Immune Activation in Second-Line HAART HIV+ Patients Is Similar to That of Untreated Patients.Quantifying Adaptive and Innate Immune Responses in HIV-Infected Participants Using a Novel High Throughput AssayMicrobial translocation, immune activation, and HIV disease.Rate of AIDS progression is associated with gastrointestinal dysfunction in simian immunodeficiency virus-infected pigtail macaquesAlterations in the levels of vesicular trafficking proteins involved in HIV replication in the brains and CSF of patients with HIV-associated neurocognitive disorders.HDAC inhibitors in HIV.Chloroquine and beyond: exploring anti-rheumatic drugs to reduce immune hyperactivation in HIV/AIDS.Predict disease progression from T-cell phenotypes in northern pig-tailed macaques (Macaca leonina) during SIVmac239 infection.Chronic Hepatitis C Virus Infection and the Proinflammatory Effects of Injection Drug Use.Inflammatory Markers Related to Microbial Translocation Among HIV-Infected Pregnant Women: A Risk Factor of Preterm Delivery.Minocycline attenuates HIV-1 infection and suppresses chronic immune activation in humanized NOD/LtsZ-scidIL-2Rγ(null) mice.GP73 is a potential marker for evaluating AIDS progression and antiretroviral therapy efficacy.The Dual Role of Neutrophils in HIV Infection.
P2860
Q26865388-847155C9-63AA-4447-8084-4E15EACE13AEQ27014077-F1224A6C-B47A-44D9-BFAC-8ECD466C2832Q27312050-010183F0-D57A-4FDE-A995-F63F04DD8371Q28274045-2DCF635D-FC45-4B86-AA74-8AA23F27FED7Q30009511-870200F5-DB5D-42B7-9848-BD6E46BE1FB8Q30381883-6B648257-D117-49A8-9BC0-D7AFFBDEE80EQ33632786-F0A72A7A-B1EF-483B-88B0-D919326FF7ABQ33798584-08C7D1D3-D8C2-45AB-8A88-D4E77D93C04DQ34020121-0ED60BD8-CAAA-4509-9621-BC923E6DC635Q34105477-795D846A-A690-417C-B705-24482AB8D6B3Q34351320-E1D2359A-946D-4AA4-8808-61C010F257D0Q34428634-0B3583E7-2CC4-4088-9FE3-304A4645DF4EQ34575989-66D856E9-AD57-44D5-97C3-A96ED13FA7CBQ35191924-A8542628-EC01-429E-A76E-435CACE1F8E6Q35264787-49538282-62DF-4F9A-B1D5-B4D8E6AD7F3AQ35273346-C185CF04-9656-4FCE-A782-4A301F64E48DQ35822412-4DD3DAA9-1A09-403E-BCC7-9D794593B1AAQ35833324-8FC6A137-671B-4582-B69C-C2003EBE7F0EQ35873402-BED5AD0D-A207-4742-B1B6-13260F705C93Q36217715-0E82E36E-888E-491E-9CF2-5638DAA042F1Q36501286-6A6FF7F2-43C3-47BA-81A2-6871CF9BC747Q36881002-D8A1B1E3-BD49-4519-8FAE-E43B746C89F9Q37680586-AB64064C-A693-4D7F-8BC7-395305872C24Q37956178-9498F4FE-2C8F-4290-8B12-2AE32C4DE171Q38530430-16A08878-D421-40BA-AD5C-CC09253EDCFAQ40123019-9F16152A-079D-4B2F-9B39-FDBE5D4FD978Q40577279-A7CEF11F-44B7-47C9-AE97-721536BDE2FCQ41057213-E0BDAE11-D2B9-42DF-8971-F4CDACC4FD11Q42233499-7D466F8D-113D-4852-B4F4-DAC072EF70DEQ42266868-E3E00E35-D456-4F3F-B34F-9BFC95CDFD53Q54260140-F719A3F0-1C80-490F-AD14-95982DB3696D
P2860
Biomarkers of immune dysfunction following combination antiretroviral therapy for HIV infection.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Biomarkers of immune dysfuncti ...... ral therapy for HIV infection.
@en
Biomarkers of immune dysfuncti ...... ral therapy for HIV infection.
@nl
type
label
Biomarkers of immune dysfuncti ...... ral therapy for HIV infection.
@en
Biomarkers of immune dysfuncti ...... ral therapy for HIV infection.
@nl
prefLabel
Biomarkers of immune dysfuncti ...... ral therapy for HIV infection.
@en
Biomarkers of immune dysfuncti ...... ral therapy for HIV infection.
@nl
P2093
P2860
P921
P356
P1476
Biomarkers of immune dysfuncti ...... ral therapy for HIV infection.
@en
P2093
Gregor F Lichtfuss
Jennifer Hoy
Marit Kramski
Suzanne M Crowe
P2860
P304
P356
10.2217/BMM.11.15
P577
2011-04-01T00:00:00Z